BPG is committed to discovery and dissemination of knowledge
Clinical Trials Study
©The Author(s) 2025.
World J Cardiol. Nov 26, 2025; 17(11): 109287
Published online Nov 26, 2025. doi: 10.4330/wjc.v17.i11.109287
Table 1 General data on the included patients, n (%)
Characteristic
Overall (n = 128)
Observation group (n = 55)
Control group (n = 73)
P value
Age (year), mean ± SD63 ± 1062 ± 1164 ± 60.42
Male95 (74)40 (73)67 (92)0.09
Type of lesion0.71
Non-STEMI95 (74)40 (73)55 (76)
STEMI33 (26)15 (27)18 (24)
Heart rate (bpm), mean ± SD72 ± 1671 ± 1672 ± 170.01
Systolic pressure (mmHg), mean ± SD114 ± 21114 ± 20119 ± 220.27
Diastolic pressure (mmHg), mean ± SD73 ± 1671 ± 976 ± 70.14
Left ventricular ejection fraction (%), mean ± SD47 ± 1047 ± 1047 ± 110.47
Creatinine (mmol/L), mean ± SD72 ± 2272 ± 2479 ± 100.21
Pulmonary arterial hypertension15 (12)6 (11)9 (12)0.62
Diabetes mellitus22 (17)9 (16)13 (18)0.76
Dyslipidemia42 (33)17 (31)25 (34)0.22
Smoking42 (33)24 (44)18 (25)0.62
Family history of coronary artery disease44 (34)19 (35)25 (34)0.42
Antithrombotics
Aspirin92 (72)34 (62)58 (79)-
Clopidogrel46 (36)20 (36)26 (36)1.00
Direct oral anticoagulant6 (5)2 (4)4 (5)0.42


Write to the Help Desk